drugset / Trial / NCT07349069
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with intermediate or high risk early breast cancer.
Timeline
- Start
- 2026-03-04
- Primary completion
- 2030-12
- Completion
- 2034-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anastrozole | Other / unclassified | — | — |
| Comparator | Exemestane | Small molecule | — | — |
| Subject | HRS-8080 | Unknown | — | — |
| Comparator | Letrozole | Other / unclassified | — | — |
| Comparator | Tamoxifen | Small molecule | — | — |